Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout [Seeking Alpha]
SELLAS Life Sciences Group, Inc. (SLS)
Last sellas life sciences group, inc. earnings: 11/14 04:41 pm
Check Earnings Report
US:NYSE Investor Relations:
sellaslifesciences.com/investors/overview/default.aspx
Company Research
Source: Seeking Alpha
GPS is an immunotherapy drug targeting the Wilms Tumor 1 antigen, which is overexpressed in AML patients. The AML market size is estimated to be $3.1 billion. The upcoming interim readout of the GPS phase 3 clinical trial in April could significantly impact the valuation of the drug, with a successful trial potentially increasing its value to $1.5B. SELLAS Life Sciences Group, Inc. NASDAQ: SLS ) is a late-stage biotech company offering us a GPS lottery ticket with an estimated 9x return and 44% probability of success. The ticket is time-sensitive, as their leading drug candidate Galinpepimut-S (GPS) phase 3 clinical trial interim report is scheduled to be read out in the upcoming days/weeks. As quick overview, Sellas has two clinical stage cancer drugs that could provide solutions to areas of unmet need. Fortunately for us, my investment thesis can be made on their leading candidate alone, of which I'll focus this write-up on. The Problem - AML AML, Acute Myeloid Leukemia,
Show less
Read more
Impact Snapshot
Event Time:
SLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLS alerts
High impacting SELLAS Life Sciences Group, Inc. news events
Weekly update
A roundup of the hottest topics
SLS
News
- SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level [Yahoo! Finance]Yahoo! Finance
- SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose LevelGlobeNewswire
- SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 StudyGlobeNewswire
- SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewswire
SLS
Sec Filings
- 5/2/24 - Form EFFECT
- 5/2/24 - Form EFFECT
- 4/30/24 - Form ARS
- SLS's page on the SEC website